

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CSPC PHARMACEUTICAL GROUP LIMITED

### 石藥集團有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

#### VOLUNTARY ANNOUNCEMENT

### **INDICATION FOR ACUTE ISCHEMIC STROKE OF MINGFULE (明復樂®) (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) OBTAINS MARKETING APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mingfule (明復樂®) (recombinant human TNK tissue-type plasminogen activator for injection) (rhTNK-tPA) ( $1.0 \times 10^7$  IU/16 mg/injection) (the “**Product**”) developed by CSPC Reomgen Pharmaceutical (Guangzhou) Co., Ltd.\* (石藥集團明復樂藥業(廣州)有限公司), a subsidiary of the Company, has obtained marketing approval granted by the National Medical Products Administration of the People’s Republic of China for the new indication of thrombolytic treatment in patients with acute ischemic stroke (onset <4.5h). It is the first approval for this indication of this product type in China, and is the second approved indication of the Product in China following its indication for acute myocardial infarction.

The approval of this new indication is based on the efficacy and safety results of a well-designed, large-scale pivotal phase III clinical trial. The results of the study have been published in *The Lancet*, a top-level international medical journal.

The Product, a third-generation thrombolytic drug, is a recombinant protein produced by genetic engineering using mammalian cells. Compared with alteplase (rt-PA), the Product has a longer half-life, stronger antagonistic capability of plasminogen activator inhibitor-1 (PAI-1) and stronger fibrin binding ability. The administration of the Product is convenient by single bolus intravenous injection within 5-10 seconds, which enables a faster intravenous thrombolytic treatment and a shorter transit time for patients with acute ischemic stroke, demonstrating significant clinical application advantages.

The approval of this new indication adds another key product to the Group's portfolio in the field of cerebrovascular disease, offers a new treatment option for patients with acute ischemic stroke (onset <4.5h) and improves drug accessibility, bringing benefits to more patients.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 5 February 2024

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*

*\* For identification purpose only.*